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Abstract
Using phages is a novel field of cancer therapy and phage nanobioparticles (NBPs) such as l phage could be modified to
deliver and express genetic cassettes into eukaryotic cells safely in contrast with animal viruses. Apoptin, a protein from
chicken anemia virus (CAV) has the ability to specifically induce apoptosis only in carcinoma cells. We presented a safe
method of breast tumor therapy via the apoptin expressing l NBPs. Here, we constructed a l ZAP-CMV-apoptin
recombinant NBP and investigated the effectiveness of its apoptotic activity on BT-474, MDA-MB-361, SKBR-3, UACC-812
and ZR-75 cell lines that over-expressing her-2 marker. Apoptosis was evaluated via annexin-V fluorescent iso-thiocyanate/
propidium iodide staining, flow-cytometric method and TUNEL assay. Transfection with NBPs carrying l ZAP-CMV-apoptin
significantly inhibited growth of all the breast carcinoma cell lines in vitro. Also nude mice model implanted BT-474 human
breast tumor was successfully responded to the systemic and local injection of untargeted recombinant l NBPs. The results
presented here reveal important features of recombinant l nanobioparticles to serve as safe delivery and expression
platform for human cancer therapy.
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Introduction
Phages are a family of viruses that can only infect bacteria (there
are 1031 of them) [1]. These nanobioparticles (NBPs) are extremely
host specific and each type could infect specific species of a
bacterium. Lambda (l) is a temperate phage with a double
stranded DNA genome. It’s composed of glycoprotein E (gpE) and
gpD coat proteins [2]. Lambda NBPs have high production
capacity, high degree of stability, rapid and inexpensive produc-
tion process and biological safety in human cells [3]. They are
considered poor vehicles for transduction of eukaryotic cells [4]
but the construction of phagemid vectors has made their
manipulation easy [5]. Using phages is an attractive field of
cancer therapy; but little is known about the bacteriophage
mediated gene expression in eukaryotic cells. We therefore
performed experiments to examine l phage mediated apoptin
expression both in vitro and in vivo.
Apoptosis is frequently occuring in many human tumor cells. It
is also an important mechanism in chemotherapy for malignant
cell death. Therefore, modulation of apoptosis by targeting pro-
apoptotic and anti-apoptotic proteins is a powerful tool for treating
cancers. It has been reported that an anti-cancer protein, apoptin,
to induce the selective death of cell lines including melanoma,
hepatoma, lymphoma, cholangiocarcinoma, colon carcinoma and
lung cancer [6–8]. Apoptin was named because it was shown to
induce apoptosis in tumorigenic human cells. Apoptin is a small
protein of 121 amino acids (13 kDa) derived from chicken anemia
virus (CAV) [9,10]. CAV is one of the smallest avian viruses and
does not grow in common cell lines. Its genome encodes three viral
proteins (VP1-3) [11] that VP3 is also known as apoptin [10]. Its
apoptotic activity is linked to its ability to localize in the nuclei of
transforming cells, but not in the healthy human normal cells
[12,13].
Apoptin-mediated cell death is independent of death receptors
such as FADD (Fas dependent death) or caspase-8, the key
regulators of the extrinsic apoptotic pathway [14]. Phosphorylated
Nur77 could transmit apoptotic signal from the nucleus to
mitochondria, as it was shuttled from the nucleus to the cytoplasm
upon transient expression of apoptin. Moreover, down-regulation
of Nur77 protected against apoptin induced apoptosis [14]. Nur77
may cause cytochrome c release and activation of the apoptosome
dependent death pathway. Apoptin is phosphorylated at threonine
108 in tumor cells [15]. This tumor-specific phosphorylation cause
tumor-specific nuclear localization and apoptotic activity [15].
Apoptin involves caspase-3 that bypasses most of the upstream
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components of the apoptotic pathway [16]. Also it is influenced by
regulators of the mitochondrial pathway like Apaf-1 that triggers
cytochrome c release and activation of caspase-9 [17]. Apoptin
interacts with the SH3 domain of p85, the regulatory component
of phospho-inositide 3-kinase (PI3-K), through its proline-rich
region [18]. Down-regulation of p85 cause nuclear exclusion of
apoptin and impairs apoptosis, indicating that the interaction with
the p85 is essential for cytotoxic activity of apoptin [18]. Over-
expression of anti-apoptotic genes (bcl-2, BAG-1 or bcr-abl) did not
protect neoplastic cells from apoptin-induced apoptosis [17,19,20].
Also apoptin is independent of p53. Thus, apoptin is a potential
therapeutic for the treatment of cancers, including those contain-
ing defects in any of the mentioned anti-apoptotic genes. Apoptin
has advantages in contrast to conventional therapies that rely on
the intact cellular apoptotic machinery such as chemotherapy or
radiation.
Apoptin gene can be inserted into various vectors such as
parvoviruses, papilomaviruses, polyomaviruses and adenoviruses
[21,22], making it attractive for cancer therapy. To use apoptin in
cancer therapy, efficient delivery to tissues and proper expression
of apoptin in neoplasms is required. Here we report the
construction of a recombinant l phage NBP expressing apoptin
gene efficiently in breast cancer cell lines without targeting process.
Breast cancer is a heterogeneous carcinoma and thousands of
genes may contribute to breast cancer pathophysiology, but
subsets of tumors show the same patterns of genomic and
biological abnormality [23]. So we tested the apoptotic effects of
NBPs on BT-474, MDA-MB-361, SKBR-3, UACC-812 and ZR-
75 that are her-2 over-expressing cell lines. The in vivo studies were
performed on BT-474 tumor bearing nude mice model.
Apoptin maintains its specificity for carcinoma cells when
introduced and expressed by l NBPs.
Results
Production of the recombinant l NBPs
To generate NBPs expressing apoptin, the recombinant plasmid
l ZAP-CMV containing the apoptin gene was constructed
(Figure 1A). The restriction endonuclease digestion pattern
showed that apoptin gene was inserted correctly into the vector.
Figure 1. Design and Construction of NBPs harboring l ZAP-CMV-apoptin expression plasmid. (A) The expression vector was
subsequently inserted into the l phage, generating the recombinant NBPs, (B) Different cell types were infected with the indicated recombinant l
NBPs at an MOI of 10 PFU/cell and apoptin transcription was analyzed by RT-PCR, (C) RT-PCR result for l ZAP-CMV vector treated cells that have no
expression of apoptin, (D) Western blot analysis to detect apoptin protein from cells supernatants and lysates. To analyze apoptin expression, the
cells were infected with the indicated recombinant NBPs. Purified apoptin was used as a positive control and CAV infected BT-474 cell was used as a
negative control.
doi:10.1371/journal.pone.0079907.g001
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The recombinant plasmid l ZAP-CMV-apoptin was packaged
into NBPs and then transfected into various breast carcinoma cell
lines. These cells were her-2 positive and were expressed proteins
involved in signaling processes and in cell-cell interactions. MDA-
MB-361 has the highest and ZR-75 has the lowest expression
levels of her-2 marker (Unpublished data). The correct transcrip-
tion and translation of apoptin was determined by reverse
transcriptase polymerase chain reaction and western blot analysis.
The apoptin transcripts (mRNA) were detected in all carcinoma
cells harboring l ZAP-CMV-apoptin. Bone marrow stem cell
(BMSC) that was the only non-neoplastic cell did not express
apoptin mRNA (Figure 1B, C). In the western blot analysis all the
carcinoma cell lines expressed apoptin except the CAV infected
BT-474 cell. Also BMSC as a negative control has not any
expression of apoptin (Figure 1D).
Anti neoplastic effect of NBPs
The anti neoplastic effect of l NBPs was studied via
morphological changes of cells using annexin-V fluorescein
antibody and propidium Iodide (PI) and also flowcytometry for
cultured cells in vitro. The immunofluorescent staining using the
polyclonal antiserum in NBPs transfected cells showed expression
of apoptin inside the nuclei of the transformed cells. NBPs
transfected cells showed morphological changes of apoptosis
(Figure 2). The expression of apoptin did not completely disappear
after 36 h, but at this time between 40–70% of the cancer cells
were dying. The study revealed clearly that apoptin was expressed
by NBPs that harbors l ZAP-CMV-apoptin cassette. No such
changes were observed in l ZAP-CMV vector treated groups.
Also there was no expression of apoptin in BMSC treated NBPs
(Figure 2). Annexin-V fluorescein/PI staining confirmed the
apoptosis in the transformed cells. PI staining revealed color
changes in BT-474 apoptotic cells (Figure 3A). Various lengths of
transfections were compared for their effect on cell viability. The
MTT colorimetric assay was performed to detect cell viability after
transfection. When cells treated with l NBPs the growth of the
BT-474 cell line was inhibited by 20% after 24 h, 50% after 48 h
and more than 70% after 96 h. As expected, with longer
transfection times, the growth of the cells was inhibited
(Figure 3B). The SKBR-3 cell line was inhibited by 15% after
24 h and about 65% after 96 h. The most inhibition of cell growth
was seen in the MDA-MB-361 cell line by only 10% survival rate
(Figure 3B). In contrast, the recombinant l NBPs had no effect on
BMSCs viability. There was no significant difference in the
neoplastic cell viability after transfection with l ZAP-CMV pure
vector and non treated group as the negative control (Figure 3B).
Also the viability of cells after NBPs treatment was investigated in
three breast carcinoma cell lines by flowcytometry. As shown in
the Figure 4, BT-474, SKBR-3 and ZR-75 cells were susceptible
to NBPs-induced apoptosis. The l ZAP-CMV vector lonely didn’t
Figure 2. FITC immunostaining of apoptin expression in breast carcinoma cell lines. Immunostaining of apoptin protein showed that in
can express in breast carcinoma cell lines after 12 h. There was apoptotic morphology of these cell lines after 36 h of NBPs transfection. The cell lines
that treated with l ZAP-CMV vector have not any apoptosis after 36 h as same as untreated cells.
doi:10.1371/journal.pone.0079907.g002
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affect cell viability and there was no change in the non-treated
group. The flowcytometric assay confirmed the apoptosis results
obtained from previous studies (Figure 4).
Cytotoxicity of NBPs
To determine the cytotoxicity of the l ZAP-CMV-apoptin
plasmid and only the l phage they were transfected into BT-474
cells separately. The apoptosis of BT-474 cells was observed after
transfection with of l ZAP-CMV-apoptin plasmid (Figure 5),
while in contrast l ZAP-CMV plasmid and the only l phage had
no effect on the cell survival (Figure 5). Therefore l NBPs not
seems to exhibit cytotoxicity in cells and the apoptosis is induced
by l ZAP-CMV-apoptin construct due to expression of apoptin
only in the malignant cell nucleus (Figure 5).
Nude mice model for the study of recombinant NBPs
effect
To investigate the ability of the recombinant NBPs in vivo, we
injected NBPs into the tail vein (Intra Venous; IV) of mice bearing
BT-474 human breast tumor and then recovered them after
perfusion. The circulation time for NBPs is just 1 hour after IV
injection. We determined the titers of the phage in tumors and
normal organs as control sites (kidney, liver, brain and heart).
NBPs showed not specific homing site (Figure 6) and recovered
from all the mice organs even in the local intramuscular (IM)
injected mice (after 6 hours), but surprisingly they were recovered
from more percentage from the tumor site (Figure 6). The
circulation time for NBPs is about 6 hours after IM injection.
Figure 3. Cell viability and apoptosis after NBPs treatment. (A) Apoptosis in BT-474 breast carcinoma cell line induced by l NBPs. The right
side indicates NBPs treated group and Left side image indicates control group, (B) Cell viability determined by MTT dye reduction assay.
doi:10.1371/journal.pone.0079907.g003
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Angiogenesis studies showed significantly higher expression of
CD34 marker in immunohistochemical analysis that demonstrates
neo-vascularization system in BT-474 tumors (Figure 7). CD34 is an
indicator of vascularization density in tissues. After a time and
enlargement in tumor size there is an increase in tissue vascular-
ization (Figure 7). Treatment of animals with NBPs caused a
decrease in the number of CD34 positive cells. Measuring the tumor
size in animals showed that recombinant NBPs markedly inhibited
the tumor growth (Figure 8A) but there were no changes in the
control group to inhibit the progressive rate of effect to tumor
growth (Figure 8A). Histology samples revealed that 100 mg of NBPs
inhibited tumor growth completely and induced apoptosis in the
Figure 4. Confirmation of apoptosis by flowcytometry. BT-474, SKBR-3 and ZR-75 cells were examined after 36 h of transfection by
flowcytometry. All the cell lines were susceptible to NBPs apoptin-induced apoptosis. We have not apoptosis in vector treated group and untreated
group.
doi:10.1371/journal.pone.0079907.g004
Figure 5. Cytotoxicity evaluation of plasmid and vehicle. BT-474
breast carcinoma cell line transfected with l ZAP-CMV-apoptin, l ZAP-
CMV vector and l phage (vehicle) construct stained with FITC
immunostaining and then visualized by fluorescence microscopy. There
was no sign of cell necrosis after the treatments. There is only apoptotic
morphology of cells after treatment with l ZAP-CMV-apoptin.
doi:10.1371/journal.pone.0079907.g005
Figure 6. Recovery of NBPs from nude mice tissues. There were
no significant differences in recombinant NBPs titer that was recovered
from the different tissues of the treated mice. The tumor site was the
only part of the mice body to support the more NBPs accumulation.
doi:10.1371/journal.pone.0079907.g006
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tumor cells, but the same concentration of a control phage had no
inhibitory effect (Figure 9A). The results were revealed that the
NBPs have restricted neoplastic cells only in 96 h after treatment
(Figure 9A). There was no effect of apoptosis in the brain and heart
tissues of recombinant NBP treated mice in histochemistry assays
(Figure 9B). To determine the apoptotic cells in the tumor tissues,
also sections of the tumors were prepared for TUNEL assay. From
the Figure 10A it is obvious that mice received recombinant NBPs
contained many TUNEL positive cells in the tumor site, while in
untreated tumors there were not TUNEL positive cells (Figure 10A).
The tumors in mice that received recombinant NBPs were
significantly smaller than those in the control groups (P#0.05)
(Figure 8B). The tumor sizes in the IM and IV injected groups were
4 and 2.8 times smaller than control groups, respectively
(Figure 8C).
Finally, we compared the survival rates of tumor bearing nude
mice after treatment with recombinant NBPs or control groups over
a period of three months. All the tumor model animals in the
untreated group died (survival rate 0%). Six of ten mice were
survived even after three months in the NBPs treated group (survival
rate 60%) and their tumor was suppressed completely (Figure 10B).
Discussion
Efficacy and specificity is an important requirement for
successful cancer therapy. Here, we discuss the in vitro and in vivo
transfection of the human breast neoplastic cells with the
untargeted recombinant l nanobioparticles carrying l ZAP-
CMV-apoptin construct. These NBPs resulted in an effective
induction of apoptosis selectively in tumor cells.
Selective centralization in cancer cells while sparing normal cells
is an emerging field in recent years. Apoptin is a new anti-cancer
tool with great potential to destroy only cancerous cells
[12,13,27,28]. However efficient systems are required to deliver
apoptin to the cancer cells or express apoptin within these cells.
We suggested l nanobioparticles for this purpose. In our study, the
construction and characterization of recombinant l phage for
gene delivery and expression in mammalian cells is reported.
In the 1940s, Bloch showed that phages could inhibit growth of
tumors in animals [29]. These results were confirmed by
Dabrowska et al who showed that phages inhibited growth of
B16 tumors by blocking integrins necessary for metastasis [30]. It
has been shown that bacteriophage-mediated DNA vaccination
gives rise to antibody levels that are higher than those produced
after vaccination with a commercially available recombinant
protein vaccine [31]. Phage displaying human immunodeficiency
virus (HIV) mimotopes (peptides that mimic the structure of an
antigenic epitope), corresponding to epitopes from the C-terminus
of glycoprotein 120 (gpl20) of HIV have also been used to elicit
antiviral antibodies [32]. March et al took the approach of using
unmodified lambda to deliver a genetically encoded hepatitis B
surface antigen (HBsAg) into mice and they then monitored the
immune response against the encoded antigen, which induced a
high humoral response in mice [33]. These findings outline the
versatility of phage-based vaccines. Of course our work is so
different from all of these works. Our recombinant NBPs can cure
the breast cancer affected region by inducing apoptosis in
neoplasmic cells without transferring any antigen or mimicking
the epitopes of cancer cell markers that are the targets of cancer
Figure 7. Evaluation of angiogenesis in tumor tissue. The nude mice were sacrificed and tumor samples collected at the end of the treatment
period. Tissues were prepared and stained for CD34 as described in Materials and Methods. The tumor tissue develops angiogenesis. Amount of
CD34 positive cells increases with a time.
doi:10.1371/journal.pone.0079907.g007
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therapy. Because the goal of our work was not to elicit the immune
responses of the host (Humoral or cell mediated immunity
responses). This makes our NBPs unique in cancer therapy.
As described, the filamentous phages have been used for gene
delivery vectors in some cases but there are few reports about using
lambda phages for this purpose. Recently we showed that lambda
phage could express nanobody against her-2 positive breast
carcinoma cells [34]. In this work the human breast carcinoma
was stopped efficiently by l NBPs but there was no apoptosis in
normal cells (BMSCs). Also pure l ZAP-CMV vector had not
apoptotic effects on the neoplasmic cells (Figure 2). Our developed
l vector encoding apoptin gene can efficiently express the apoptin
protein in the eukaryotic cells especially in carcinoma cells
(Figure 1B,C,D). In 2007 scientists treated melanoma tumors
with genetically engineered phages that were able to accumulate in
tumors and express some genes [35]. l NBPs delivered apoptin
gene was expressed in a functional form in human breast
carcinoma cell lines (Figure 3A). It is an unconventional approach
for cancer gene therapy that is based on the tumor specific activity.
Surprisingly the l NBPs were not targeted for the carcinoma cells
but there was no expression in control cells (Figure 1B,C,D). The
reason correlates with the cellular localization of the apoptin. In
normal cells, it resides dominantly in the cytoplasm, but in tumors,
it localizes to the nucleus [12,13]. Also the phage distribution was
higher in the tumor site of our model (Figure 6). The first reason
for this phenomenon should be the high metabolism and excess
blood circulation in the tumor site. As our data shows tumor sizes
in the IM and IV injected groups were 4 and 2.8 times smaller
than control groups, respectively (Figure 8C). Probably in IM
injection the recombinant NBPs circulate in the tumor site and
enter the neoplasmic cells in this region more effectively. In IV
injection the NBPs circulate in whole body and a significant
amount of them distribute to the other sites. However a significant
number of these particles accumulate in the tumor site. The
second reason could be explained by the studies from Eriksson and
colleagues [35]. They observed regression of tumors after
treatment with phages with no specificity for the tumor [35].
They suggested that the anti-tumor activities are mediated by the
host immune system through tumor infiltrating neutrophils. The
recruitment of the immune system is highly dependent on the
phage accumulation at the tumor site [35]. Since phages are
regarded as foreign by the immune system, the inflammatory
process initiates near the tumor that contains inflammatory
proteins. The phenomenon could partly be explained by the
‘‘danger model’’ [36] which suggest that tumor trauma or
infectious agents may result in regression of tumors. Also we
found more results about binding untargeted phages in the cancer
cells both in vitro and in vivo. There are some reports that
demonstrate the phage attachment into the plasma membrane of
lymphocytes [37,38]. It has been demonstrated that some phages
possess in their structure proteins containing a KGD motif, which
is a ligand for the b3 integrins on eukaryotic cells [39]. The tumor
selectivity of apoptin renders it suitable for systemic therapy, which
in the case of l phage delivery and expression; there is no need for
specific targeting. So it would be cost effective and preferable
pharmaceutical choice.
From the point that the breast cancer is a heterogeneous
disease, the use of different cancer cells without considering their
phenotypes is a common problem neglected in many cases. The
cell lines in our panel were selected for their ability to express
her-2 and proliferate to form clinically relevant and invasive
tumors in women.
As shown in Figure 3B, the viability of carcinoma cells treated
with recombinant l ZAP-CMV-apoptin NBP significantly has
reduced, compared to BMSC (*P#0.05). The MTT results
showed that the growth of the BT-474 cell line was inhibited by
70% after 96h. As expected, with longer transfection times, the
Figure 8. Determination of tumor size in nude mice. (A)
Treatment of nude mice bearing human breast cancer xenografts with
BT-474. Injection of BT-474 breast carcinoma cells to the nude mice
resulted in the growth of xenografts. The Tumors were injected 3 times
a week with 109 PFU of recombinant NBPs, only vector and PBS.
Hereafter, tumor growth was measured regularly, (B) Volumes of the
BT-474 tumor tissue during treatment. Median tumor volume is
determined over time in all treated groups. Tumor volumes were
calculated using the equation: Length6width260.52, (C) The effects of
different treatments on change in body weight over the treatment
period. Average body weight was calculated for each treatment group
at the indicated time points.
doi:10.1371/journal.pone.0079907.g008
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growth of the cells was inhibited more and more (Figure 3B). The
SKBR-3 cell line was inhibited by 65% after 96h and the most
inhibition of neoplastic cells was seen in the MDA-MB-361 by
only 10% survival rate after 96 h (Figure 3B). Our expressed
apoptin selectively caused apoptosis in the human BT-474, MDA-
MB-361, SKBR-3, UACC-812 and ZR-75 cell lines. In contrast,
normal BMSC was not done under apoptotic process and
maintained their differentiation potential in multi lineage colony
formation assays (Figure 2). These results that confirmed by
flowcytometry (Figure 4) indicate that recombinant NBPs could
induce significant anti-cancer effects than treatment with control
groups (l ZAP-CMV vector and untreated groups). Also NBPs
didn’t exert any cytotoxic effect on normal cells. The cytotoxicity
of the plasmid and vector phage was not significant in treated cells
(Figure 5).
There are no other reports about apoptin expression and its
delivery by l phages, but others have reported that cholangio-
carcinoma cells can be transduced by adenovirus [40]. Also there
Figure 9. Immunohistochemical results of NBPs treated animals. (A) Histochemistry analysis of tumor tissue sections showing apoptotic
changes. The untreated tumor tissue contains many dividing cells. After 96 h treatment with NBPs there are a few cells maintained in the tumor
tissue that could proliferate. Tumor growth was markedly suppressed in the apoptin treated group, (B) Histological examination of other organs
(brain and heart) in tumor bearing mice that is not involved in the pathological changes of BT-474 cells. There are no changes in morphology of the
brain and/or heart tissues and they are as same as control groups.
doi:10.1371/journal.pone.0079907.g009
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is a report that has shown replication deficient adenovirus vectors
expressing apoptin have significant antitumor effects against
xenografted hepatoma, in some cases leading to complete
regression [41]. There is another reason for higher accumulation
of NBPs in tumor site rather than other tissues. The results of
neo-vascularization confirmed the significantly higher expression
of CD34 marker in BT-474 tumors compared to non tumor
tissues (Figure 7). Also immunohistochemical result revealed that
there is an increase in tumor tissue vascularization after
enlargement in tumor size after time (Figure 7). Enlargement
in tumor size due to a rapid proliferation gives rise to hypoxic
areas inside the tumor, which demands increased nutrients and
oxygen supply. We suggest that the extensive angiogenesis and
neo-vascularization could trap the recombinant NBPs. Tumor
vessels have a high proportion of proliferating endothelial cells,
lack of pericytes and improper basement membrane formation
leading to an enhanced permeability. Nanoparticles (in the size
range of 10–400 nm), can extravasate and accumulate inside the
interstitial space of tumor because endothelial pores have sizes
varying from 10 to 1000 nm. In addition, lymphatic vessels are
absent or non-functional in tumors which cause inefficient
drainage from the tumor tissue. Nanoparticles entered into the
tumor site are not removed efficiently and are thus retained in
the tumor. This passive phenomenon has been called the
‘‘Enhanced Permeability and Retention (EPR) effect,’’ discovered
by Matsumura and Maeda [42–44]. Selective accumulation of
our NBPs then occurs by the EPR effect. The EPR effect is
becoming the gold standard in cancer-targeting drug designing
and for almost all solid tumors (with the exception of prostate
cancer and/or pancreatic cancer) [43,45]. Very high local
concentrations of nanocarriers can be achieved at the tumor,
for instance 10–50 folds higher than in normal tissue [46]. So
EPR is one reason for accumulation of recombinant NBPs in the
BT-474 tumor site.
Our in vivo studies in nude mice showed that the concentration
of NBPs in the tumor tissue was more than other tissues (Figure 6).
It’s true that untargeted NBP construct recovered from all body
organs of treated mice, but immunohistochemistry analysis has
shown its apoptotic effect only in the tumor tissues and there was
no change in other tissues after NBPs treatment (Figure 9A,B). We
thought that histochemistry and TUNEL analyses are useful to
study the changes of apoptosis in tumors. The morphology of
condensed, spherical nuclear chromatin structures inside the cells
reveals the apoptosis. Increase in NBPs accumulation in tumor
tissues correlates with the increase in therapeutic efficacy. It
decreased the tumor size (Figure 8A, B, C) and induced many
TUNEL positive cells (Figure 10A) that decreased the mice death
rate to 40% in comparison with control cases (Figure 10B). Finally
further improvements in definition of the proper dose of the
apoptin expressing NBPs could help to develop apoptin as an anti-
cancer drug.
Conclusion
This report describes the construction of a recombinant l
nanobioparticle that express apoptin and induce apoptosis only in
transformed cells without targeting process. With this approach,
we achieved in efficient regression of breast tumors with a
combination of apoptin and l nanobioparticles. Specificity of
apoptin compensates targeting of phage vector and thus providing
proof of principle that this agent can be used as a safe and
inexpensive source of tumor therapy.
Materials and Methods
Strains and media
Escherichia coli DH5a (Pasture Institute, Tehran, Iran) was used
as a host for l phage amplification and titration purposes. The
Luria-Bertani (LB) (Sigma-Aldrich, USA) and 2YT media
(Invitrogen, USA) was supplemented with 100 mg/ml ampicillin
(Sigma, USA) and kanamycin (Santa Cruz, USA) for the selection
of transformants. The LB medium (supplemented with 0.01M
MgCl2) and M9-medium (supplemented with ampicillin and
isopropyl-b-D-1-thiogalactoside; IPTG) were used as electropora-
tion and expression medium, respectively. Chicken anemia virus
(CAV) that harbors apoptin gene was a gift from the Veterinary
campus of Tehran University (Tehran, Iran).
Cells and cell culture
The breast carcinoma cell lines (BT-474, MDA-MB-361,
SKBR-3, UACC-812 and ZR-75) (Pasture Institute, Tehran,
Iran) and normal mouse bone marrow stem cell (BMSC, Lonza
Figure 10. The survival rate of nude mice bearing human
breast cancer. (A) TUNEL analysis revealed that apoptin induces the
apoptotic activity in neoplasms (Magnification: 6400), (B) Analysis of
survival. Mice treated with NBPs survived longer than the mice in the
other 2 groups and the mean survival of NBPs-infected mice were
.90 days (p,0.005). Fifty days after the beginning of the treatment,
90% of the animals infected by NBPs were alive, while at this time 100%
of vector treated mice and 100% of saline-treated mice had died.
Tumor-bearing mice treated with saline had a mean survival of 50 days.
doi:10.1371/journal.pone.0079907.g010
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Clonetics, USA) were grown in RPMI 1640 complete medium
(Invitrogen, USA) and DMEM/F12 (Gibco, UK) containing 10%
fetal bovine serum (FBS, Gibco, UK) at 37uC and 5% CO2.
BMSC was used as a non-neoplastic cell that did not express her-2
marker as a negative control.
PCR amplification of the apoptin gene
PCR amplification of the apoptin gene was carried out using the
primer set that was designed based on the sequences in GenBank
(NC-001427), and synthesized by Cinnagen Inc (Tehran, Iran).
The first pair of designed primers was: (sense) 59-ATGAAT-
GAACGCTCTGCAGGAAGATACTCC-39 and (antisense) 59-
CTTCAGTCTTATACGCCTTTTTGCGG-39. The expected
product size was 396 bp containing the complete apoptin open
reading frame. The reaction mixture was prepared in PCR buffer
containing 2 mM MgCl2, 200 mM dNTPs and 20 pmol of
primers. Taq polymerase (1unit; Promega, USA) and template
DNA (5 ng) from CAV were added to a total reaction volume of
25 ml. The reaction was carried out in an automated thermal
cycler (Peq Lab, Germany) with an initial denaturation for
three minutes followed by 35 cycles of denaturation at 95uC for
one minute, annealing at 60uC for one minute and extension at
72uC for one minute and the final extension was carried out at
72uC for five minutes. A specific PCR-amplified product was
purified from the gel by using a gel-extraction kit (QIAex II,
Qiagen) and was used for cloning.
Cloning of the apoptin gene
The PCR product gel-purified apoptin was cloned into the
pCR2.1 vector (Invitrogen, USA). The plasmids were trans-
formed into E. coli DH5a by electroporation. The apoptin cDNA
cloned in pCR2.1 vector was confirmed by restriction enzyme
digestion and by DNA sequencing. The insert was released from
the pCR2.1 vector by digesting with BamH-I restriction enzyme
and the released product was purified from the gel. It was ligated
into BamH-I and HinD-III digested l ZAP-CMV expression
vector (Stratagene, USA) using 2U of T4 DNA ligase (Fermentas,
USA) and 0.5 ml of 10 mM ATP (Invitrogen, USA). Then it was
electroporated into electrocompetent DH5a and plated for
separation of individual clones as described previously [24].
Construction of recombinant l NBPs
To generate the recombinant l NBPs by homologous recom-
bination; DH5a E. coli was infected with 1 multiplicity of infection
(MOI) of l nanobioparticles (Nanjing, China) and after 2 h
incubation at 37uC, electroporated with 10 mg l ZAP-CMV-
apoptin. The ligated expression vector (l ZAP-CMV-apoptin) was
added to the packaging extract. The l ZAP-CMV-apoptin tube
was incubated at room temperature for 2 h. One ml of phage
buffer [included 5.6 g NaCl, 2.0 g MgSO4,7H2O, 50.0 ml 1.0 M
Tris-HCl (pH 7.5), 5.0 ml gelatin 2% (w/v) in 1 l distilled water]
was added to the tube. Then, 20 ml of chloroform (Sigma, USA)
was added and mixed the contents of the tube, gently. The tube
was spined and the supernatant containing the NBPs was ready for
titration. NBPs were titrated by plating the infected DH5a on agar
plates (Gibco, USA) according to the manufacturer’s instructions.
Large scale NBPs containing l ZAP-CMV-apoptin expressing
vector was conducted in 1 l of M9 medium (Sigma-Aldrich, USA)
containing ampicillin (Sigma, USA). After 24 h the culture was
induced by adding 1 mM IPTG and was incubated a further 72 h.
Induced culture was centrifuged at 8500 g for 30 min. The NBPs
present in this extract was purified by immobilized metal affinity
chromatography (Qiagen, USA). One clone was selected for high
expression of the apoptin gene as determined by both western blot
and reverse transcription-polymerase chain reaction (RT-PCR).
In vitro expression studies
Human BT-474, MDA-MB-361,SKBR-3, UACC-812 and ZR-
75 cell lines were cultured in RPMI-1640 (BT-474, SKBR-3, ZR-
75) and DMEM complete medium (MDA-MB-361, UACC-812).
The cells achieved 80% confluence at 24 h in the six-well culture
plates. BMSC (without her-2 expression) was cultured in DMEM/
F12 showing 80% confluency after 36 h. All the cultures were used
for expression study of the l ZAP-CMV-apoptin cloned vector.
Serial phage dilutions ranging from ,108 M to 1012 M were
prepared in calcium buffer (2 mM CaCl2, 150 mM NaCl, 10 mM
HEPES, 3 mM NaN3, pH 7). The monolayer cells were harvested
from plates and transferred into microtubes and then infected by
recombinant NBPs containing l ZAP-CMV-apoptin cassette. The
contents of tubes were then mixed together and kept at room
temperature for 15 min. The mixtures were cultured in the six-
well plates in previously described media containing 5% FBS.
After 4 h incubation, the medium over the cells was removed and
fresh medium was added. At the end of 48 h, medium was
removed completely; cells were used for RT-PCR, western blot
and immunocytochemistry analyses.
Identification of recombinant NBPs by RT-PCR
The transfected host cells were rinsed twice with phosphate
buffer saline (PBS) and total RNA was isolated from cells using an
RNeasy total RNA Extraction Kit (Qiagen, Germany) according
to the manufacturer’s instructions. One microgram of total RNA
was reverse transcribed to first-strand cDNA with Superscript
reverse transcriptase (Invitrogen, USA) as described in manufac-
turer description order. For the RT-PCR analysis, 5 mg of total
RNA were reverse transcribed by using MMLV reverse
transcriptase (Promega, USA). RNA equivalent cDNA (500 ng)
was amplified by PCR using Taq DNA polymerase (Cinnagen,
Iran) for 30 cycles under the following conditions: 95uC for 5 min,
55uC for 30 sec and 72uC for 1 min. b-actin was used as a
housekeeping gene. PCR products were run on 1.5% agarose gel
containing ethidium bromide and photographed using an imaging
system.
Western blot analysis for apoptin detection
After 36 h post transfection, recombinant l NBP transfected
cells were subjected to blotting analysis as described previously
[25]. Briefly the cells were washed with phosphate buffer saline
and then posed into 100 ml lysis buffer (50 mM Tris, pH 7.4,
250 mM NaCl, 5 mM EDTA, 0.1% Triton X-100, 20 mM b-
glycerophosphate, 1 mM phenyl-methyl-sulphonyl-fluoride,
200 mg/ml trypsin inhibitor), transferred into a microtube and
kept on ice for 30 min. Samples were boiled in sample buffer
(50 mM Tris, pH 7.4, 2% SDS, 100 mM dithiothreitol, 0.1%
bromophenol blue, 10% glycerol) for 5 min and cell debris was
removed by centrifugation at 12000 g at 4uC for 10 min. Samples
were loaded onto 10% SDS PAGE and blotted with mouse
polyclonal anti-apoptin antibody for 2 h followed by incubation
with goat anti-mouse IgG antibody (Santa Cruz, USA) labeled
with HRP for 2 h. Pure apoptin was used as a positive control,
CAV infected cells was used as a negative control and b-actin was
used as internal control.
Anti neoplastic effect of recombinant NBPs
The in vitro effect of apoptin in cells transfected by recombinant
l NBPs revealed as follows: Cells were plated on coverslips in
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dishes the day before transfection. Transfection was carried out
using recombinant NBPs containing l ZAP-CMV-apoptin.
Twelve hours after transfection, and after that in 12 h interval
cells were stained with FITC Annexin-V and propidium iodide
(PI), mounted on slides, and observed by using a fluorescence
microscope. Percent apoptosis were scored as the percent of 100
FITC fluorescence-positive cells showing apoptotic morphology.
MTT colorimetric assay
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazo-
lium bromide, Sigma, USA) assay was performed to detect cell
viability after recombinant NBPs transfection. The all kinds of host
cells were seeded in 96-well plates (104cells per well) one day
before cells were transfected with recombinant NBP. Cell viability
was measured every 12 h over a 96 h period by treating cells with
20 ml MTT (5 mg/ml) and incubating for 4 h at 37uC to allow
MTT metabolization. The culture media was removed and the
crystals formed was dissolved by adding 100 ml dimethylsulfoxide
(DMSO, Merck, Germany) per well. The absorbance at 490 nm
was measured with an enzyme-linked immunosorbent assay
(ELISA) plate reader. Untreated cells were used as controls and
all measurements were performed in triplicate.
Flowcytometry assay
The changes in the membrane of apoptotic cells was determined
by using an Apoptosis assay kit (Invitrogen, USA). The NBP
expressing apoptin transfected BT-474, SKBR-3 and ZR-75
carcinoma cells were stained with Fluorscein annexin-V conjugate
violet ratio metric asymmetry probe and the nuclei of the
apoptotic cells were stained with red fluorescence. After staining,
the cell suspensions were analyzed on a BD-flowcytometer. Viable
cells were defined as annexin-V fluorescent iso-thiocyanate (FITC)
negative events.
NBP cytotoxicity assay
Cytotoxicity of l ZAP-CMV-Apoptin NBPs, l ZAP-CMV and
only l phage particles was tested by FITC fluorescence-positive
cells showing apoptotic morphology. Transfected cells were placed
on a 6-well plate, were washed with PBS and apoptotic cells that
were differentiated by morphological changes visualized by
fluorescence microscope.
In vivo experiments on nude mice model
Thirty two nude mice were injected subcutaneously with BT-
474 cells. The mice bearing breast cancer xenografts (,2 cm3)
divided into three study groups. One group was injected
intravenous (IV) and intramuscular (IM) with 109 PFU of the
recombinant l constructs and another group was taking control
phage. The third study group of tumor bearing mice only injected
with PBS. All the treatments were done for three days a week for
30 days. Mice body weights and tumor sizes were measured twice
a week. Tumor volumes were calculated using the equation:
Length 6 width2 60.52. In another study the xenograft tumors
and other mouse organs (Brain and Heart) were removed and
homogenized after perfusion. The NBPs bound to each tissue
sample were recovered through the addition of host bacteria and
titered on agar plates and expressed as PFU per gram of each
tissue. Finally, the tumor tissues were prepared for histology
analysis, detection of neo-vascularization and TUNEL (Tdt-
mediated dUTP nick end labeling) assay. The samples were
collected in 10% formalin and proper sections were made with a
microtome. The sections were stained and studied for apoptotic
changes under the light microscope. TUNEL was performed with
the use of the in situ cell death detection kit (Roche, Mannheim,
Germany), as described previously [26]. TUNEL staining was
colored by means of 3-amino-9-ethylcarbozole. Next, by micro-
scopic analysis the cells were examined for cell death induction.
For detection of angiogenesis or neo-vascularization some sections
of tumor tissues were then washed with PBS, incubated in blocking
buffer with 5% bovine serum albumin for 20 min and probed for
60 minutes at room temperature with mouse anti CD34 antibody
(Abcam, Inc., MA). Sections were then washed and sequentially
incubated with a secondary antibody. For angiogenesis or neo-
vascularization, CD34-labeled sections from three tumors per
treatment group were visualized by light microscopy.
The handling of animals was in accordance with the Animal
Care Guidelines’ of Tehran University of Medical Sciences Ethical
Committee. All the experiments were performed in the manners
that minimize the stress and pain in animals.
Statistical analysis
The statistical significance of differences was evaluated using the
analysis of t-test with repeated measures using SPSS software
(version 10.1). The survival rates of animals after 3 month follow
up are shown in the Kaplan-Meier plot. All p-values reported were
accepted as p,0.05.
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